{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:40:21Z","timestamp":1768207221800,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009110","name":"Natural Science Foundation of Xinjiang Uygur Autonomous Region","doi-asserted-by":"publisher","award":["TSYC202301A063"],"award-info":[{"award-number":["TSYC202301A063"]}],"id":[{"id":"10.13039\/100009110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Objective<\/jats:title>\n To investigate clinical data of hospitalised cirrhosis patients, identify risk factors for cirrhosis progression to hepatocellular carcinoma, establish a risk prediction model, and provide scientific basis for early identification of high-risk patients.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Hospitalised cirrhosis patients treated at Xinjiang Uygur Autonomous Region People\u2019s Hospital between January 2019 and December 2023 were selected. Their inpatient examination records were retrieved, including medical record summaries alongside results for coagulation function, complete blood count, liver function tests, urinalysis, renal function tests, tumour markers, comprehensive hepatitis panel, comprehensive thyroid function panel, comprehensive biochemical panel, glucose series, and lipid series. Patients diagnosed with hepatic malignancy during subsequent hospitalisations (excluding the initial admission) formed the cancer progression group, while those without hepatic malignancy constituted the control group. Univariate and multivariate analyses identified risk factors for hepatocellular carcinoma (HCC) progression in cirrhosis patients. A predictive model for HCC development in cirrhosis patients was constructed using a combined Lasso regression model and Bayesian network model.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n This study enrolled 1,204 individuals, including 1,128 cirrhosis patients, of whom 76 progressed to liver malignancy. Multivariate logistic regression analysis indicated that female gender was a protective factor against cirrhosis progression to liver malignancy(\n OR<\/jats:italic>\n = 0.532,\n OR<\/jats:italic>\n 95%\n CI<\/jats:italic>\n = 0.297-0.952); while hepatitis B, elevated total cholesterol, and reduced antithrombin III activity were risk factors for progression to hepatocellular carcinoma (\n OR<\/jats:italic>\n = 4.080,\n OR<\/jats:italic>\n 95%\n CI<\/jats:italic>\n = 2.443-6.814;\n OR<\/jats:italic>\n = 2.308,\n OR<\/jats:italic>\n 95%\n CI<\/jats:italic>\n = 1.132-4.707,\n OR<\/jats:italic>\n = 2.982,\n OR<\/jats:italic>\n 95%\n CI<\/jats:italic>\n = 1.389-6.402) (\n P<\/jats:italic>\n &lt; 0.05); The LASSO regression model ultimately identified 14 variables most significantly associated with the transformation of cirrhosis into malignant liver tumours: PT, TT, MAO, ALP, PDW, CRP, CK-MB, Ca, P, TC, AFP, FT4, SCC, AT3. The results of the Bayesian network model indicate that DOI, AT3, SCC, CRP, and TC have a direct connection with the occurrence of hepatic malignancy; Gender, FT4, hepatitis type, and Ca indirectly influence the development of hepatic malignancy. Using sensitivity analysis, we examined the probability of cirrhosis patients progressing to hepatocellular carcinoma under specific conditions. The results indicated that the probability of liver cirrhosis patients progressing to hepatocellular carcinoma was 0.0749 (7.5%) when AT3 levels were normal, 0.0709 (7.1%) when AT3 was low, and 0.0850 (8.5%) when AT3 was high. When TC levels were normal, the probability was 0.0763 (7.6%), and it increased to 0.1309 (13.1%) when TC was elevated. The performance of the Bayesian network model (AUC = 0.857, Brier Score = 0.052, Accuracy = 0.940, C-index = 0.833 (95%\n CI<\/jats:italic>\n : 0.784\u20130.882), Sensitivity = 0.836, Specificity=0.744) was superior to that of the logistic regression model (AUC = 0.780, Brier Score = 0.056, Accuracy = 0.934, C-index = 0.785 (95%\n CI<\/jats:italic>\n : 0.726\u20130.843), Sensitivity = 0.727, Specificity = 0.766). Ten-fold cross-validation showed an average accuracy of 0.93. After balancing sensitivity and specificity, the optimal threshold was determined by maximizing the Youden index (0.052), with a predicted probability &gt;0.052 indicating progression from liver cirrhosis to hepatic malignancy. Based on the ROC curve, threshold 1 was set at 0.2 and threshold 2 at 0.8, establishing risk stratification as follows: low risk (predicted probability &lt;0.2), intermediate risk (0.2 \u2264 predicted probability \u2264 0.8), and high risk (predicted probability &gt;0.8). This resulted in 318 patients classified as low risk, 42 as intermediate risk, and 1 as high risk.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Gender, hepatitis B, TC, and AT3 constitute risk factors for hepatocellular carcinoma in cirrhotic patients; Gender, hepatitis type, DOI, FT4, AT3, SCC, CRP, MAO, and Ca are associated with the progression of liver cirrhosis to malignant liver tumours either directly or indirectly. The risk prediction model constructed by combining LASSO regression with Bayesian networks demonstrates good predictive value.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2025.1735042","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:45:47Z","timestamp":1768196747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of a Bayesian network-based risk prediction model for hepatocellular carcinoma in cirrhotic patients"],"prefix":"10.3389","volume":"15","author":[{"given":"Ni","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686962","article-title":"Risk factors and prevention of viral hepatitis-related hepatocellular carcinoma","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05537-2","article-title":"Disease burden of hepatocellular carcinoma: A global perspective","volume":"64","author":"Sayiner","year":"2019","journal-title":"Dig Dis Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i24.3466","article-title":"Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements","volume":"27","author":"Perisetti","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)","volume":"9","author":"Zhou","year":"2020","journal-title":"Liver Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","article-title":"Evidence-based clinical practice guidelines for Liver Cirrhosis 2020","volume":"56","author":"Yoshiji","year":"2021","journal-title":"J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00017-8","article-title":"Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis","volume":"26","author":"Dee","year":"","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27222","article-title":"Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go","volume":"60","author":"El-Serag","year":"2014","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1753-6405.1996.tb01818.x","article-title":"General practitioners\u2019 promotion of healthy life styles: what patients think","volume":"20","author":"Richmond","year":"1996","journal-title":"Aust N Z J Public Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12985-020-01393-z","article-title":"Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study","volume":"17","author":"Zheng","year":"2020","journal-title":"Virol J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-1240","article-title":"Spatial epidemiological analysis of the burden of liver cancer in China","volume":"13","author":"Meng","year":"2024","journal-title":"Transl Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21037\/hbsn-2024-754","article-title":"2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges","volume":"14","author":"Yan","year":"2025","journal-title":"Hepatobil Surg Nutr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203620","article-title":"Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics","volume":"13","author":"Macias","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"10996","DOI":"10.1038\/s41598-024-61820-x","article-title":"Serum ApoB\/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma","volume":"14","author":"Cai","year":"2024","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2016.12.029","article-title":"Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome","volume":"130","author":"Kasmari","year":"2017","journal-title":"Am J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1038\/s41467-021-26718-6","article-title":"N1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1038\/s41467-018-06931-6","article-title":"Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling","volume":"9","author":"Liang","year":"2018","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-9-226","article-title":"Inhibition of HCV by the serpin antithrombin III","volume":"9","author":"Asmal","year":"2012","journal-title":"Virol J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2009.08.025","article-title":"Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation","volume":"290","author":"Meyer-Siegler","year":"2010","journal-title":"Cancer Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112338-20210319-00233","article-title":"Analysis on hepatitis B cases reported from surveillance points in China, 2019","volume":"42","author":"Meng","year":"2021","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"B25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF03346699","article-title":"Environmental triggers of thyroiditis: hepatitis C and interferon-\u03b1","volume":"34","author":"Menconi","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00174","article-title":"Thyroid hormone in hepatocellular carcinoma: cancer risk, growth regulation, and anticancer drug resistance","volume":"7","author":"Lin","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12394","article-title":"The effect of L-thyroxine substitution on lipid profile, glucose homeostasis, inflammation and coagulation in patients with subclinical hypothyroidism","volume":"68","author":"Anagnostis","year":"2014","journal-title":"Int J Clin Pract"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/00365513.2016.1238504","article-title":"Diagnostic value of serum squamous\u00a0cell\u00a0carcinoma antigen for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"77","author":"Yu","year":"2017","journal-title":"Scand J Clin Lab Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2021.10.014","article-title":"The crosstalk between pattern-recognition receptor signaling and calcium signaling","volume":"192","author":"Kong","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.3042","article-title":"C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma","volume":"47","author":"She","year":"2015","journal-title":"Int J Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1186\/s12885-022-09939-w","article-title":"Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study","volume":"22","author":"Song","year":"2022","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1186\/s12885-020-07665-9","article-title":"A prospective follow-up study of the relationship between high-sensitivity C-reactive protein and primary liver cancer","volume":"20","author":"Siyin","year":"2020","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1735042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:45:49Z","timestamp":1768196749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1735042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1735042"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1735042","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1735042"}}